PROVECTUS BIOPHARMACEUTICALS, INC.: 10-Q filed 2014-11-06
What PROVECTUS BIOPHARMACEUTICALS, INC. reported in its quarterly report filed 2014-11-06 (fiscal Q3 2014): 21 published measures, 56 facts as tagged in accession 0001193125-14-399257.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-11-06
- Fiscal period
- fiscal Q3 2014
- Accession
- 0001193125-14-399257 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROVECTUS BIOPHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 21,647,723 | USD | |
| At 2013-12-31 | 20,008,184 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 2,108,298 | USD | |
| At 2013-12-31 | 13,379,518 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 19,539,425 | USD | |
| At 2013-12-31 | 6,628,666 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 17,773,680 | USD | |
| At 2013-12-31 | 15,696,243 | USD | |
| At 2013-09-30 | 8,253,591 | USD | |
| At 2012-12-31 | 1,221,701 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | -3,748,547 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -11,059,230 | USD | 273 |
| 2013-07-01 to 2013-09-30 | -4,552,695 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -11,100,250 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 70,590 | USD | 273 |
| 2013-01-01 to 2013-09-30 | 6,650 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | -157,110,050 | USD | |
| At 2013-12-31 | -146,050,820 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 95,555 | USD | |
| At 2013-12-31 | 30,113 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | -3,825,681 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -12,367,172 | USD | 273 |
| 2013-07-01 to 2013-09-30 | -3,650,190 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -10,183,724 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 17,773,680 | USD | |
| At 2013-12-31 | 15,696,243 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 881,061 | USD | |
| At 2013-12-31 | 512,946 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 3,751,488 | USD | |
| At 2013-12-31 | 4,254,828 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 1,358,102 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 3,541,520 | USD | 273 |
| 2013-07-01 to 2013-09-30 | 1,296,654 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 2,815,519 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 180,299,739 | shares | |
| At 2013-12-31 | 159,751,724 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 176,469,175 | USD | |
| At 2013-12-31 | 152,519,701 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 434,479 | USD | |
| At 2013-12-31 | 429,331 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-09-30 | 27,000 | USD | |
| At 2013-12-31 | 27,000 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | -3,748,547 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -11,059,230 | USD | 273 |
| 2013-07-01 to 2013-09-30 | -4,591,385 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -12,288,898 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 2,299,799 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 8,322,312 | USD | 273 |
| 2013-07-01 to 2013-09-30 | 2,185,756 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 6,864,865 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-09-30 | 5,148 | USD | 273 |
| 2013-01-01 to 2013-09-30 | 4,650 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 167,780 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 503,340 | USD | 273 |
| 2013-07-01 to 2013-09-30 | 167,780 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 503,340 | USD | 273 |
Inspect the source
- Entity
- PROVECTUS BIOPHARMACEUTICALS, INC. / CIK 0000315545
- Captured
- 2026-09-19T14:56:22.911Z
- SEC response SHA-256
5c46f06a9f23badc21fb49ef63f53fb89ac39f7570babcbf8a64cddf67fb05d2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000315545.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))